One of the early indicators for the effectiveness of Janus kinase inhibitors (JAKI) in IIM came from a case report describing a 72-year-old woman with severe muscle and cutaneous DM, diagnosed with a JAK2-V617F mutation-positive myelofibrosis one year after her DM diagnosis. The gene discussed is JAK2; the disease is dermatomyositis.